Erinacine A-enriched Hericium erinaceus mycelium ameliorates Alzheimer’s disease-related pathologies in APPswe/PS1dE9 transgenic mice

Journal of Biomedical Science

Research

Chen Wan-Ping¹  Chen Chin-Chu¹  Lee Li-Ya¹  Chen Chien-Chih²  Huang F. Chi-Ying³  Tzeng Tsai-Teng³  Young-Ji Shiao⁴  Shen Chien-Chang⁵  Lu Chung-Kuang⁵ 

[1] Biotechnology Center, Grape King Bio Ltd. Chung-Li, 320, Taoyuan, Taiwan, Republic of China;Department of Biotechnology and Department of Nursing, HungKuang University, 433, Taichung, Taiwan, Republic of China;Institute of Biopharmaceutical Science, National Yang-Ming University, 112, Taipei, Taiwan, Republic of China;Institute of Biopharmaceutical Science, National Yang-Ming University, 112, Taipei, Taiwan, Republic of China;National Research Institute of Chinese Medicine, Ministry of Health and Welfare, 112, Taipei, Taiwan, Republic of China;Ph.D Program for the Clinical Drug Discovery from Botanical Herbs, College of Pharmacy, Taipei Medical University, 110, Taipei, Taiwan, Republic of China;National Research Institute of Chinese Medicine, Ministry of Health and Welfare, 112, Taipei, Taiwan, Republic of China;

关键词: Alzheimer’s disease;    APPswe/PS1dE9 transgenic mice;    Amyloid β;    Neurogenesis;    Hericium erinaceus;    Insulin-degrading enzyme;   

DOI  :  10.1186/s12929-016-0266-z

 received in 2016-02-19, accepted in 2016-06-15,  发布年份 2016

来源: Springer

【 摘 要 】

BackgroundThe fruiting body of Hericium erinaceus has been demonstrated to possess anti-dementia activity in mouse model of Alzheimer’s disease and people with mild cognitive impairment. However, the therapeutic potential of Hericium erinaceus mycelia on Alzheimer’s disease remains unclear. In this study, the effects of erinacine A-enriched Hericium erinaceus mycelia (HE-My) on the pathological changes in APPswe/PS1dE9 transgenic mouse model of Alzheimer’s disease are studied.ResultsAfter a 30 day oral administration to 5 month-old female APPswe/PS1dE9 transgenic mice, we found that HE-My and its ethanol extracts (HE-Et) attenuated cerebral Aβ plaque burden. It’s worth noting that the attenuated portion of a plaque is the non-compact structure. The level of insulin-degrading enzyme was elevated by both HE-My and HE-Et in cerebral cortex. On the other hand, the number of plaque-activated microglia and astrocytes in cerebral cortex and hippocampus were diminished, the ratio of nerve growth factor (NGF) to NGF precursor (proNGF) was increased and hippocampal neurogenesis was promoted after these administrations. All the mentioned benefits of these administrations may therefore improve the declined activity of daily living skill in APPswe/PS1dE9 transgenic mice.ConclusionsThese results highlight the therapeutic potential of HE-My and HE-Et on Alzheimer’s disease. Therefore, the effective components of HE-My and HE-Et are worth to be developed to become a therapeutic drug for Alzheimer’s disease.

【 授权许可】

CC BY   
© The Author(s). 2016